Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035383 | 0.99 | LMNA (0.48) | LMNAMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6036040 | 0.94 | MAPT (0.56) | LMNAMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6036200 | 0.85 | KMT2A (0.48) | MAPTALDH1A1SMN1; SMN2KMT2APOLB | |
| SCHEMBL6035188 | 0.84 | ALDH1A1 (0.50) | CYP1A2CYP2D6CYP2C9ALDH1A1KMT2A | |
| SCHEMBL6035676 | 0.84 | CYP1A2 (0.49) | CYP1A2CYP2D6CYP2C9KMT2ANPSR1 | |
| SCHEMBL6036408 | 0.84 | CYP1A2 (0.49) | LMNACYP1A2CYP2D6CYP2C9KMT2A | |
| SCHEMBL6035976 | 0.83 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C9ALDH1A1KMT2A | |
| SCHEMBL6036039 | 0.83 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C9KMT2ANPSR1 | |
| SCHEMBL6035295 | 0.83 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C9ALDH1A1KMT2A | |
| SCHEMBL6035694 | 0.83 | MAP2K1 (0.47) | MAPTALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993437-B1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1140291-B1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER LAMBERT CO (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1140062-B1 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1143957-A3 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1143957-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1140067-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140046-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140062-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140291-A1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035435-A9 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER LAMBERT CO (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0993437-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001421-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |